ESR1 and breast cancer: Tamoxifen, a SERM that acts by blocking the ER, has been ubiquitously used over the last four decades as the treatment of choice in pre-menopausal BC patients, although in the adjuvant setting, it was the drug of choice in post-menopausal women with HR+ BC (10, 11).